Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
Nimodipine
Bayer Australia Ltd
Medicine Registered
NIMOTOP ® CMI 1 NIMOTOP ® (NEE·MOE·TOP) _nimodipine_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Nimotop. This leaflet does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Nimotop against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR, NURSE OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again WHAT NIMOTOP IS USED FOR Nimotop tablets and infusion solution are used to prevent or to treat a lack of blood supply in the brain caused by narrowing of the blood vessels after a haemorrhage (burst blood vessel in the brain). This medicine belongs to a group of drugs called calcium channel blockers. Nimotop works by relaxing the smooth muscle of the small blood vessels in the brain. This allows narrowed vessels to open up, thereby increasing blood flow, reducing blood pressure, and improving circulation. YOUR DOCTOR MAY PRESCRIBE THIS MEDICINE FOR ANOTHER USE. IF YOU WANT MORE INFORMATION, ASK YOUR DOCTOR. If you have any further questions on your Nimotop treatment, or are unsure of the information, please see your doctor, nurse or dispensing pharmacist, who will be able to assist you. BEFORE YOU TAKE NIMOTOP _WHEN YOU MUST NOT TAKE IT _ DO NOT TAKE NIMOTOP TABLETS OR INFUSION SOLUTION IF YOU HAVE AN ALLERGY TO: nimodipine, the active ingredient in Nimotop any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include: shortness of breath wheezing or difficulty breathing swelling of the face, lips, tongue or oth Lugege kogu dokumenti
110401 NIMOTOP PI 1 PRODUCT INFORMATION NIMOTOP ® NIMODIPINE NAME OF THE MEDICINE Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is isopropyl (2 - methoxyethyl) 1, 4 - dihydro - 2, 6 - dimethyl - 4 - (3 - nitrophenyl) - 3, 5 - pyridine - dicarboxylate. It is a racemic mixture with a molecular weight of 418.5 and a molecular formula of C 21 H 26 N 2 O 7 . The CAS Registry Number is: 66085-59-4. The structural formula is: DESCRIPTION Nimodipine is a yellow crystalline substance, practically insoluble in water. Nimodipine is light sensitive but to a much lesser degree than nifedipine. Nimotop is available as tablets containing 30 mg nimodipine or a 0.2 mg/mL solution for infusion. Nimotop tablets contain cellulose – microcrystalline, povidone, starch - maize, crospovidone, magnesium stearate, hypromellose, macrogol 4000, titanium dioxide and iron oxide yellow as excipients. Nimotop solution for infusion contains ethanol 96% (200 mg/mL), macrogol 400, sodium citrate and citric acid – anhydrous as excipients. PHARMACOLOGY Nimodipine is a calcium channel blocking agent belonging to the 1,4-dihydropyridine group. The mechanism(s) of nimodipine's clinical benefit in patients with subarachnoid haemorrhage has not been fully elucidated. Current evidence suggests that it may have a preferential cerebral vasodilator action and/or a direct effect involving prevention of calcium overload in neurons. It dilates the small resistance cerebral vessels and increases the cerebral blood flow, the increased perfusion being generally more pronounced in brain regions with preliminary damage and restricted circulation than in healthy Lugege kogu dokumenti